Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Genitourinary Cancer Services — Clinical Trials

Novel Treatment Combination Study for Metastatic Prostate Cancer Patients

A phase II randomized study of overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of LY2157299 and enzalutamide.

Prostate Cancer Study

Phase 3, double blind trial, using investigational product in asymptomatic subjects with Gleason sum equal to or lesser than 7, metastatic androgen independent prostatic adenocarcinoma

Radiation Therapy Treatment Study for Stage III-IV Prostate Cancer

A phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer.

SBRT for Localized Prostate Cancer Study

A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.

Study of Combination Therapy for High Risk Prostate Cancer

Niraparib with standard combination radiation therapy and androgen deprivation therapy in treating patients with high risk prostate cancer.

Study of Standard Systemic Therapy in Treating Prostate Cancer

Phase III randomized trial of standard systemic therapy (SST) versus standard systemic therapy plus definitive treatment (surgery or radiation) of the primary tumor in metastatic prostate cancer.

Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer

Phase III trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer (mCRPC).

Treatment Study for Patients with Metastatic Castration Resistant Prostate Cancer

A phase 1b/2 study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide or abiraterone/prednisone in patients with metastatic castration resistant prostate cancer.

Treatment Study for Patients with Prostate Cancer

Phase II-III trial of adjuvant radiotherapy following radical prostatectomy with or without adjuvant docetaxel.

Treatment Study for Patients with Prostate Cancer with DNA Repair Defects

A randomized phase II trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.